NCT06759480

Brief Summary

Radical hysterectomy is an effect treatment for FIGO IB3 and IIA2 cervical cancer patients who refuse to receive radical concurrent chemoradiotherapy. However, due to the large tumor size, both patients and surgeons encountered the risk of substantial bleeding, urinary tract damage, and unsatisfactory resection during surgery. Therefore, the exploration of effective and safe surgical treatments is crucial in enhancing the quality of life and prognosis for patients. Laparoscopic radical hysterectomy (LRH) offers the advantages of reduced bleeding and accelerated recovery, thereby minimizing patient discomfort and enhancing their quality of life. However, the prognosis of patients who received LRH or traditional abdominal radical hysterectomy (ARH) remains controversial. We proposed a modified LRH skill based on new space anatomy concept. In our previous single-center study, the result demonstrates that LRH based on space anatomy leads to less intraoperative blood loss and decreased ureteral injury rate compared with traditional skill. The benefits of this new method for patient survival remain uncertain. In this multicenter retrospective study, we aim to assess clinical prognosis and safety of this new LRH compared with traditional abdominal radical hysterectomy (ARH) in FIGO IB3 and IIA2 cervical cancer.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 27, 2024

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

December 28, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 6, 2025

Completed
9 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2025

Completed
Last Updated

January 6, 2025

Status Verified

December 1, 2024

Enrollment Period

19 days

First QC Date

December 28, 2024

Last Update Submit

January 3, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Overall survival

    The time from end of surgery to death from any cause.

    5 years

  • Progression-free survival

    The time from end of surgery to either the first documented disease progression or death from any cause.

    5 years

Secondary Outcomes (2)

  • Surgery complication rate

    Intraoperative or within 2 weeks after surgery

  • Intraoperative blood loss

    Intraoperative blood loss

Study Arms (2)

LRH group

In this group, patients received a modified laparoscopic radical hysterectomy(LRH) based on space antomy.

Procedure: Laparoscopic radical hysterectomy based on space anatomy

ARH group

In this group, patients received a traditional abdominal radical hysterectomy(ARH). ARH group is defined as a control group.

Procedure: Abdominal radical hysterectomy

Interventions

This is a modified laparoscopic radical hysterectomy based on space anatomy. By identifying the vesicouterine ligament and four associated special spaces, the ureter can be completely liberated from the external aspect of the uterus. This skill not only reduces rate of surgical complications but also facilitates optimal tumor resection.

LRH group

This producre is a classic and traditional radical hysterectomy.

ARH group

Eligibility Criteria

Age20 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who clinically diagnosed with IB3 and IIA2 cervical cancer are retrospectively collected from electronic medical records of four tertiary medical center from January 2012 to January 2022

You may qualify if:

  • Aged between 20 to 70 years
  • Preoperative clinical diagnosis was FIGO 2018 stage IB3 or IIA2 cervical cancer;
  • Patients who received standard Querleu-Morrow type C radical hysterectomy (including ARH or LRH based on space anatomy) and pelvic lymphadenectomy;
  • no preoperative suspected lymph nodes metastasis, parametrial involvement or lower 1/3 vagina involvement.

You may not qualify if:

  • patients who had active double cancer or uncontrolled serious concurrent disease that might compromise prognosis;
  • pregnancy;
  • incomplete radical surgery;
  • follow-up time less than 6 months or lost to follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 28, 2024

First Posted

January 6, 2025

Study Start

December 27, 2024

Primary Completion

January 15, 2025

Study Completion

March 15, 2025

Last Updated

January 6, 2025

Record last verified: 2024-12